Breast Cancer with Neoductgenesis: Histopathological Criteria and Its Correlation with Mammographic and Tumour Features

Introduction. Breast cancer with mammographic casting type calcifications, high grade DCIS with an abnormal number of ducts, periductal desmoplastic reaction, lymphocyte infiltration, and tenascin-C (TN-C) overexpression has been proposed to represent a more aggressive form of breast cancer and has been denominated as breast cancer with neoductgenesis. We developed histopathological criteria for neoductgenesis in order to study reproducibility and correlation with other tumour markers.Methods. 74 cases of grades 2 and 3 DCIS, with or without an invasive component, were selected. A combined score of the degree(s) of concentration of ducts, lymphocyte infiltration, and periductal fibrosis was used to classify cases as showing neoductgenesis, or not. Diagnostic reproducibility, correlation with tumour markers, and mammographic features were studied.Results. Twenty-three of 74 cases were diagnosed with neoductgenesis. The kappa value between pathologists showed moderate reproducibility (0.50) (95% CI; 0.41–0.60). Neoductgenesis correlated significantly with malignant type microcalcifications and TN-C expression (P=0.008and 0.04) and with ER, PR, and HER2 status (P<0.00001for all three markers).Conclusions. We developed histological criteria for breast cancer with neoductgenesis. Neoductgenesis, by our applied histopathological definition was related to more aggressive tumour biology and malignant mammographic calcifications.

Download Full-text

A positive conversion in Hormone Receptor and HER2 status and other metastatic sites might have a impact on survival for breast cancer patients with ovarian metastases

Journal of Gynecology Obstetrics and Human Reproduction ◽

10.1016/j.jogoh.2021.102090 ◽

2021 ◽

Vol 50 (4) ◽

pp. 102090

Author(s):

Kadri Altundag

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Hormone Receptor ◽

Her2 Status ◽

Breast Cancer Patients ◽

Ovarian Metastases ◽

Impact On Survival ◽

Metastatic Sites

Download Full-text

Integrated multi‐omics profiling of high‐grade estrogen receptor‐positive, HER2−negative breast cancer

Molecular Oncology ◽

10.1002/1878-0261.13043 ◽

2021 ◽

Author(s):

Kang Wang ◽

Lun Li ◽

Sebastià Franch‐Expósito ◽

Xin Le ◽

Jun Tang ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

High Grade ◽

Estrogen Receptor Positive

Download Full-text

Loco-regional recurrence trend and prognosis in young women with breast cancer according to molecular subtypes: analysis of 1099 cases

World Journal of Surgical Oncology ◽

10.1186/s12957-021-02214-5 ◽

2021 ◽

Vol 19 (1) ◽

Author(s):

Yang Li ◽

Su Lu ◽

Yuhan Zhang ◽

Shuaibing Wang ◽

Hong Liu

Keyword(s):

Breast Cancer ◽

Local Recurrence ◽

Molecular Subtypes ◽

Early Stage ◽

Young Patients ◽

Distant Metastases ◽

Early Stage Breast Cancer ◽

Regional Recurrence ◽

Her2 Status ◽

Over Time

Abstract Background The number of young patients diagnosed with breast cancer is on the rise. We studied the rate trend of local recurrence (LR) and regional recurrence (RR) in young breast cancer (YBC) patients and outcomes among these patients based on molecular subtypes. Methods A retrospective cohort study was conducted based on data from Tianjin Medical University Cancer Institute and Hospital for patients ≤ 35 years of age with pathologically confirmed primary invasive breast cancer surgically treated between 2006 and 2014. Patients were categorized according to molecular subtypes on the basis of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status. The 5-year rates for LR, RR, and distant metastases (DM) were estimated by Kaplan-Meir statistics. Nelson-Aalen cumulative-hazard plots were used to describe local recurrence- and distant metastasis-free intervals. Results We identified 25,284 patients with a median follow-up of 82 months, of whom 1099 (4.3%) were YBC patients ≤ 35 years of age. The overall 5-year LR, RR, and DM rates in YBC patients were 6.7%, 5.1%, and 16.6%, respectively. The LR and RR rates demonstrated a decreasing trend over time (P = 0.028 and P = 0.015, respectively). We found that early-stage breast cancer and less lymph node metastases increased over time (P = 0.004 and P = 0.007, respectively). Patients with HR−/HER2+ status had a significantly higher LR (HR 20.4; 95% CI, 11.8–35.4) and DM (HR 37.2; 95% CI, 24.6–56.3) at 10 years. Breast-conserving surgery (BCS) or mastectomy did not influence rates of LR and RR. In the overall population, the 5-year survival of YBC patients exceeded 90%. Conclusions The rates of LR and RR with YBC patients demonstrated a downward trend and the proportion of early-stage breast cancer increased between 2006 and 2014. We report the highest LR rates in this young population were associated with HR−/HER2+ tumors.

Download Full-text

VWCE as a potential biomarker associated with immune infiltrates in breast cancer

Cancer Cell International ◽

10.1186/s12935-021-01955-3 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Qin Huo ◽

Zhenwei Li ◽

Siqi Chen ◽

Juan Wang ◽

Jiaying Li ◽

...

Keyword(s):

Breast Cancer ◽

Immune Cell ◽

Her2 Status ◽

Cancer Tissue ◽

M2 Macrophage ◽

Breast Cancer Patients ◽

Immune Infiltration ◽

Potential Biomarker ◽

Significant Difference ◽

Factor C

Abstract Purpose Von Willebrand Factor C and EGF Domains (VWCE) is an important gene that regulates cell adhesion, migration, and interaction. However, the correlation between VWCE expression and immune infiltrating in breast cancer remain unclear. In this study, we investigated the correlation between VWCE expression and immune infiltration levels in breast cancer. Methods The expression of VWCE was analyzed by the tumor immune estimation resource (TIMER) and DriverDB databases. Furthermore, genes co-expressed with VWCE and gene ontology (GO) enrichment analysis were investigated by the STRING and Enrichr web servers. Also, we performed the single nucleotide variation (SNV), copy number variation (CNV), and pathway activity analysis through GSCALite. Subsequently, the relationship between VWCE expression and tumor immunity was analyzed by TIMER and TISIDB databases, and further verified the results using Quantitative Real-Time PCR (RT-PCR), Western blotting, and immunohistochemistry. Results The results showed that the expression of VWCE mRNA in breast cancer tissue was significantly lower than that in normal tissues. We found that the expression level of VWCE was associated with subtypes, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) status of breast cancer patients, but there was no significant difference in the expression of VWCE was found in age and nodal status. Further analyses indicated that VWCE was correlated with the activation or inhibition of multiple oncogenic pathways. Additionally, VWCE expression was negatively correlated with the expression of STAT1 (Th1 marker, r = − 0.12, p = 6e−05), but positively correlated with the expression of MS4A4A (r = 0.28, p = 0). These results suggested that the expression of VWCE was correlated with immune infiltration levels of Th1 and M2 macrophage in breast cancer. Conclusions In our study, VWCE expression was associated with a better prognosis and was immune infiltration in breast cancer. These findings demonstrate that VWCE is a potential prognostic biomarker and correlated with tumor immune cell infiltration, and maybe a promising therapeutic target in breast cancer.

Download Full-text

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?

Case Reports in Gastrointestinal Medicine ◽

10.1155/2015/132030 ◽

2015 ◽

Vol 2015 ◽

pp. 1-6 ◽

Cited By ~ 3

Author(s):

Yu Ishimine ◽

Akira Goto ◽

Yoshito Watanabe ◽

Hidetaka Yajima ◽

Suguru Nakagaki ◽

...

Keyword(s):

Breast Cancer ◽

Gastric Cancer ◽

Residual Tumor ◽

Her2 Status ◽

Resected Specimen ◽

Her2 Positive ◽

Curative Intent ◽

Course Of Disease ◽

Trastuzumab Therapy ◽

Her2 Positivity

Trastuzumab has recently been introduced as a treatment for HER2-positive metastatic and/or unresectable gastric cancer (MUGC); however, compared with breast cancer, some issues concerning HER2 and trastuzumab therapy for gastric cancer remain unclear. A 74-year-old woman received trastuzumab-containing chemotherapy for HER2-positive MUGC. She had a marked response to 8 months of chemotherapy, and gastrectomy and hepatic metastasectomy with curative intent were performed. The resected specimen showed complete loss of HER2 positivity in the residual tumor. For MUGC, a change in HER2 status during the course of the disease with or without chemotherapy has rarely been reported. However, in breast cancer, a significant frequency of change in HER2 status during the course of disease has been reported, and reevaluation of HER2 positivity in metastatic/recurrent sites is recommended. The choice of trastuzumab for MUGC is currently based on the HER2 status of the primary tumor at the time of initial diagnosis, without reassessment of HER2 status during the course of disease and/or in metastatic/recurrent sites, on the assumption that HER2 status is stable. However, our case casts doubt on the stability of HER2 in gastric cancer.

Download Full-text

Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort

npj Breast Cancer ◽

10.1038/s41523-021-00252-6 ◽

2021 ◽

Vol 7 (1) ◽

Author(s):

Thomas Grinda ◽

Natacha Joyon ◽

Amélie Lusque ◽

Sarah Lefèvre ◽

Laurent Arnould ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Large Scale ◽

Tumour Progression ◽

Primary Tumour ◽

Multivariable Analysis ◽

Real Life ◽

Metastatic Breast ◽

Her2 Status ◽

Risk Of Death

AbstractExpression of hormone receptor (HR) for estrogens (ER) and progesterone (PR) and HER2 remains the cornerstone to define the therapeutic strategy for breast cancer patients. We aimed to compare phenotypic profiles between matched primary and metastatic breast cancer (MBC) in the ESME database, a National real-life multicenter cohort of MBC patients. Patients with results available on both primary tumour and metastatic disease within 6 months of MBC diagnosis and before any tumour progression were eligible for the main analysis. Among the 16,703 patients included in the database, 1677 (10.0%) had available biopsy results at MBC diagnosis and on matched primary tumour. The change rate of either HR or HER2 was 27.0%. Global HR status changed (from positive = either ER or PR positive, to negative = both negative; and reverse) in 14.2% of the cases (expression loss in 72.5% and gain in 27.5%). HER2 status changed in 7.8% (amplification loss in 45.2%). The discordance rate appeared similar across different biopsy sites. Metastasis to bone, HER2+ and RH+/HER2- subtypes and previous adjuvant endocrine therapy, but not relapse interval were associated with an HR discordance in multivariable analysis. Loss of HR status was significantly associated with a risk of death (HR adjusted = 1.51, p = 0.002) while gain of HR and HER2 discordance was not. In conclusion, discordance of HR and HER2 expression between primary and metastatic breast cancer cannot be neglected. In addition, HR loss is associated with worse survival. Sampling metastatic sites is essential for treatment adjustment.

Download Full-text